Tommaso Giarratano

Padova, 35128, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 30 publications

Tumor infiltrating lymphocytes as a predictor of adjuvant avelumab efficacy in patients with high-risk triple negative breast cancer.

Tumor infiltrating lymphocytes as a predictor of adjuvant avelumab efficacy in patients with high-risk triple negative breast cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 11, 2026

Long-term outcome of isolated locoregional breast cancer recurrence: a large retrospective mono-institutional study.

Long-term outcome of isolated locoregional breast cancer recurrence: a large retrospective mono-institutional study.

Journal: The oncologist

Published: January 14, 2026

PIK3CA mutations and first-line outcomes in endocrine-resistant HR+/HER2- metastatic breast cancer: A multicentric real-world study.

PIK3CA mutations and first-line outcomes in endocrine-resistant HR+/HER2- metastatic breast cancer: A multicentric real-world study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: September 09, 2025

Real-world outcomes of early-stage HER2-positive breast cancer patients treated with adjuvant paclitaxel and trastuzumab.

Real-world outcomes of early-stage HER2-positive breast cancer patients treated with adjuvant paclitaxel and trastuzumab.

Journal: NPJ breast cancer

Published: July 22, 2025

Basal-like HR + /HER2- breast cancers show higher tumor-infiltrating lymphocytes and immune signatures with potential therapeutic implications.

Basal-like HR + /HER2- breast cancers show higher tumor-infiltrating lymphocytes and immune signatures with potential therapeutic implications.

Journal: NPJ breast cancer

Published: May 28, 2025

Prognosis and Biological Characteristics of ER-Low Metastatic Breast Cancer: Results from a Multicenter Cohort and the TONIC Trial.

Prognosis and Biological Characteristics of ER-Low Metastatic Breast Cancer: Results from a Multicenter Cohort and the TONIC Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: May 15, 2025

Exceptional responses to systemic treatment in metastatic breast cancer: clinical features and long-term outcomes.

Exceptional responses to systemic treatment in metastatic breast cancer: clinical features and long-term outcomes.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 03, 2024

Development of two machine learning models to predict conversion from primary HER2-0 breast cancer to HER2-low metastases: a proof-of-concept study.

Development of two machine learning models to predict conversion from primary HER2-0 breast cancer to HER2-low metastases: a proof-of-concept study.

Journal: ESMO open

Published: October 21, 2024

Gene Expression Assays to Tailor Adjuvant Endocrine Therapy for HR+/HER2- Breast Cancer.

Gene Expression Assays to Tailor Adjuvant Endocrine Therapy for HR+/HER2- Breast Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: December 22, 2023

Association of tumor-infiltrating lymphocytes with recurrence score in hormone receptor-positive/HER2-negative breast cancer: Analysis of four prospective studies.

Association of tumor-infiltrating lymphocytes with recurrence score in hormone receptor-positive/HER2-negative breast cancer: Analysis of four prospective studies.

Journal: European journal of cancer (Oxford, England : 1990)

Published: July 24, 2023

The Impact of COVID-19 on Treatment Practices for Patients With Early Breast Cancer: A Cross-Sectional Study From a Large Cancer Center in Italy.

The Impact of COVID-19 on Treatment Practices for Patients With Early Breast Cancer: A Cross-Sectional Study From a Large Cancer Center in Italy.

Journal: The oncologist

Published: July 23, 2023

Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments.

Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments.

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 20, 2023

Showing 1-12 of 30

Last Updated: 09/26/2026